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Abstract
Background: In the present study, we compare the LMA-Protector™ and the i-gel™ in terms of adequacy of the
airway seal, insertion time, ease and accuracy of insertion, and the incidence of postoperative sore throat.
Methods: In 110 anesthetized and paralyzed adult patients, the i-gel™ (n = 55) or the LMA-Protector™ (n = 55) was
inserted. The primary outcome was airway leak pressure. The secondary outcomes included the first-attempt success
rate, insertion time, ease and accuracy of the device insertion, ease of gastric tube placement, blood staining on the
device after removal, and incidence and severity of postoperative sore throat.
Results: The airway leak pressure was higher with the LMA-Protector™ than with the i-gel™ (31 [7] cmH2O vs. 27 [6]
cmH2O, respectively; P = 0.016). Insertion time was longer with the LMA-Protector™ than with the i-gel™ (27 [16] sec vs.
19 [16] sec, respectively, P < 0.001), but ease of insertion and the first-attempt success rate were not different between
the two groups. The LMA-Protector™ provided a worse fiberoptic view of the vocal cords and more difficult gastric tube
insertion than the i-gel™ (both P < 0.001). Blood staining on the device was more frequent with the LMA-Protector™ than
with the i-gel™ (P = 0.033). The incidence and severity of postoperative sore throat were not different between the two
groups.
Conclusion: The LMA-Protector™ provided a better airway sealing effect than the i-gel™. However, it required a longer
insertion time, provided a worse fiberoptic view of the vocal cords, and caused more mucosal injury compared to the
i-gel™.
Trial registration: ClinicalTrials.gov (NCT03078517). Registered prior to patient enrollment, Date of registration: Mar 13,
2017.
Keywords: I-gel, LMA-protector™, Airway sealing
Background
The supraglottic airway device is widely used for airway
management in the anesthetic field, critical care, and
emergency situations. It is also especially effective in dif-
ficult airway management. Since the introduction of the
classic laryngeal mask airway (LMA), several innovative
supraglottic airway devices have been developed which
address such aspects as shape, quality, and function.
The i-gel™ (Intersurgical Ltd., Wokingham, UK) is made
of a medical-grade thermoplastic elastomer and designed
to anatomically fit the perilaryngeal structures with a non-
inflatable gel-like cuff that provides easier insertion and
avoids compression trauma [1]. Its advantages, including
easier insertion, minimal compression trauma, and suffi-
cient airway sealing pressure have been well identified in
the clinical practice [2–5]. The LMA-Protector™ (Teleflex
Medical, Co. Westmeath, Ireland) is a recently developed
supraglottic airway device made of medical-grade silicone
which makes it more flexible and less traumatic than previ-
ous LMA devices made of polyvinylchloride. It has a fixed,
curved structure for easier insertion with an inflatable
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airway cuff. It distinctively has two drain channels which
emerge proximally as separate ports and enter a chamber
behind the cuff bowl. This chamber narrows distally into
the orifice located at the end of the cuff which communi-
cates distally with the upper esophageal sphincter.
Additionally, the LMA-Protector™ is available with a pilot
balloon or the integrated Cuff Pilot™ that provides easier
adjustment of the intracuff pressure (Fig. 1) [6].
A preliminary assessment of the LMA-Protector™
showed that it is easy to insert and provides a reliable and
adequate seal [7], and a recent primary evaluation of the
LMA-Protector™ reported that the LMA-Protector™ pro-
vides a high pharyngeal seal [8]. However, its performance,
particularly airway sealing effect, has not been compared
with other well-identified supraglottic airway devices such
as the i-gel™. The i-gel™ has been widely used in the clinical
practice and has been reported to show a comparable
performances including airway sealing effect compared to
previous LMA devices [5, 9, 10]. We hypothesized that the
LMA-Protector™ would provide an improved airway seal
than the i-gel™, and compared the clinical performance of
the LMA-Protector™ and the i-gel™ in terms of the
adequacy of airway seal, insertion time, ease and accuracy
of insertion, and the incidence of postoperative sore throat
in paralyzed and anesthetized patients.
Methods
This study was approved by the Institutional Review Board
of our hospital (20,170,228/26–2017-33/032), and regis-
tered at ClinicalTrials.gov (NCT03078517). After obtaining
written informed consents, patients scheduled for elective
surgery under general anesthesia were recruited to the
study. The exclusion criteria were the presence of an upper
airway anatomic variation or pathology, aspiration ten-
dency (full stomach, history of stomach surgery, gastro-
esophageal reflux, hiatal hernia), a body mass index greater
than 30 kg/m2, a known or predicted difficult airway,
surgery requiring lateral or prone position, head and neck
surgery, or requirements for postoperative ventilator care.
Patients were randomly allocated to the i-gel™ or LMA-
Protector™ group, using a computer-generated program
(Random Allocation Software, ver. 1.0; Isfahan University
of Medical Sciences, Isfahan, Iran). General anesthesia
was induced with intravenous propofol 1.5–2mg/kg, fen-
tanyl 1–2 μg/kg and rocuronium 0.6mg/kg. After 100 s of
mask ventilation with sevoflurane in 100% oxygen, the i-
gel™ or LMA-Protector™ was inserted by two board-
certified staff anesthesiologists according to the manufac-
turer’s instruction. They inserted them alternately in each
group to achieve a similar distribution for using them.
The lubricated i-gel™ was inserted into the mouth and
introduced along the hard palate with a continuous and
gentle push in the sniffing position until resistance was felt
in the hypopharynx. The LMA-Protector™ was lubricated
on the posterior surface of the mask with the cuff delated.
In the sniffing position, it was introduced pressing against
the hard and soft palate with a circular motion until resist-
ance was felt in the hypopharynx. The anesthesiologists
had performed more than 30 insertions with the LMA-
Protector™ and more than 100 insertions with the i-gel™.
The size selection was made according to the manufac-
turer’s recommendation: for the i-gel™, a size three for pa-
tients less than 50 kg, a size four for those between 50 and
90 kg, and a size five for those over 90 kg; for the LMA
Protector™, a size three for patients less than 50 kg, a size
four for those between 50 and 70 kg, and a size five for
those over 70 kg [1, 6].
During insertion of the device, the following manipula-
tions were allowed: jaw thrust, adjusting insertion depth,
or head extension and flexion beyond the sniffing position.
If required, any maneuvers among the three were chosen
at the discretion of anesthesiologists. Three attempts were
allowed, and each attempt proceeded for 60 s. If the inser-
tion was not performed within 60 s, the next attempt was
Fig. 1 (a) LMA-Protector™. a, male suction port; b, female drainage port; c, integrated Cuff Pilot™ (b) Cuff of the i-gel™ and LMA-Protector™ (c)
Distal orifice of gastric channel of the i-gel™ and LMA-Protector™. Size 4 LMA-Protector™ and i-gel™ were used for this photograph
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made after manual ventilation. When the placement failed
after three attempts, the insertion was recorded as a
failure, and tracheal intubation was performed using a
direct laryngoscope. The correct insertion was assessed by
proper chest expansion, the presence of a square wave-
form on the capnogram, absence of an audible leak, and
lack of gastric insufflations, as determined by epigastric
auscultation. Insertion time was defined as the time from
picking up the i-gel™ or LMA-Protector™ to observing the
end-tidal CO2 waveform, and was calculated by adding
the time taken for each attempt. Ease of insertion was
evaluated according to the required maneuvers (jaw
thrust, adjusting insertion depth, or head extension and
flexion) during insertion as follows: easy for no maneuver,
fair for one type of maneuver, difficult for more than one
type of maneuver. The intracuff pressure of the LMA-
Protector™ was set at 60 cmH2O, and monitored and ad-
justed every 30min. The anatomic position of the devices
was evaluated using a fiberoptic bronchoscope and graded
on a scale of one to four as follows: four, only the vocal
cords seen; three, vocal cords and posterior part of the
epiglottis seen; two, vocal cords and anterior part of the
epiglottis seen; one, vocal cords not seen, but adequate
ventilation [11]. Airway leak pressure was determined by
closing the expiratory valve of the circle system at a fresh
gas flow of three L min− 1 and observing the airway pres-
sure at equilibrium by auscultating the leak sound over
the thyroid cartilage using a stethoscope. Airway pressure
was allowed up to 40 cm H2O. A lubricated gastric tube
was inserted through the gastric channel (size 12 Fr for i-
gel™, and size 14 Fr for the LMA-Protector™). The correct
placement of the gastric tube was confirmed through the
injected air by auscultation of the epigastrium and aspir-
ation of gastric content. Ease of gastric tube placement
was graded as follows: one, first attempt; two, second at-
tempt; three, impossible. Investigators who inserted the
supraglottic airway device, assessed the airway leak pres-
sure and the anatomic position of the device, and inserted
the gastric tube and the observers who recorded data were
not blinded to the group assignment. At the end of
surgery, residual neuromuscular block was reversed by
pyridostigmine and glycopyrrolate. After confirming full
recovery of the spontaneous ventilation by the presence of
regular and adequate trace of end-tidal CO2 waveform
and proper chest rise without assistance, the supraglot-
tic airway devices were removed, and the presence of
blood on the device was recorded by anesthesiologists
unblinded to the group assignment. The sore throat
was evaluated at 1 and 24 h after surgery. A 0- to 100-
mm numerical rating scale was used to evaluate the
severity of sore throat (0, no pain; 100, worst pain im-
aginable) by investigators unaware of the group alloca-
tion. Postoperative analgesic medications was recorded
for the first 24 h after surgery.
The primary outcome was the airway leak pressure. The
secondary outcomes included the success rate at the first
attempt, insertion time, ease and accuracy of supraglottic
airway device insertion, ease of gastric tube placement, the
presence of blood on the device, and incidence and sever-
ity of postoperative sore throat at 1 and 24 h after surgery.
A preliminary study was performed in 30 patients (15
per each group), and the airway leak pressure was 27.0
(6.4) cmH2O with the i-gel™ and 30.8 (6.6) cmH2O the
LMA-Protector™. Based on the results of a preliminary
study, a sample size calculation was performed assuming
as a clinically significant difference in the airway leak pres-
sure of 3.8 cmH2O between the two devices, and 50
patients per group were required at a significance level of
95% and with a power of 80%. Considering the possible
dropouts, 55 patients per group were enrolled.
SPSS version 20 for Windows (IBM, Armonk, NY, USA)
was used for the statistical analyses. Normality of the data
was tested using the Shapiro-Wilk test. Data are expressed
as mean (SD) or patient numbers (%). Student’s t-test or
Mann-Whitney U test was used to compare the airway
leak pressure, insertion time, and the severity of postoper-
ative sore throat. The number of insertion attempts, ease
of airway device, anatomic position of the device, ease of
gastric tube placement, presence of blood on the device,
and the occurrence of postoperative sore throat were
compared using the chi-square test or Fisher’s exact test.
A P-value < 0.05 was considered statistically significant.
Results
A total of 138 patients were recruited from May 2017 to
January 2018. Twenty patients did not fulfil the inclusion
criteria, and eight patients declined to participate. One
hundred and ten patients were enrolled in the study, and
included in the analysis (Fig. 2). Patient characteristics, type
of surgery, postoperative analgesic medications, and dur-
ation of surgery and anesthesia are presented in Table 1.
Data related to the device insertion are presented in Table
2. The airway leak pressure was significantly higher with
the LMA-Protector™ than with the i-gel™ (31 [7] cmH2O vs.
27 [6] cmH2O, respectively; P = 0.016) Insertion time was
significantly longer with the LMA-Protector™ than with the
i-gel™ (27 [16] sec vs. 19 [16] sec, respectively, P < 0.001),
but ease of insertion and the success rate on the first at-
tempt were not different between the two groups. During
the fiberoptic examination of the position of the devices,
the vocal cords were totally and exclusively visualized more
frequently through the i-gel™ than through the LMA-
Protector™ (80% vs. 16%, respectively; P < 0.001). Gastric
tube placement was more difficult through the LMA-
Protector™ than through the i-gel™ (P < 0.001), and it failed
in one patient through the i-gel™ and nine patients through
the LMA-Protector™. Blood staining after removal of the
devices was more often observed in the LMA-Protector™
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group than in the i-gel™ group (24% vs. 7%, respectively;
P = 0.033).
The incidence and severity of postoperative sore
throat at 1 and 24 h were not different between the
two groups (Table 3).
Discussion
This study showed that the LMA-Protector™ provides a
better airway sealing effect than the i-gel™, however, the
LMA-Protector™ required a longer insertion time, pro-
vided a worse fiberoptic view of the vocal cords, and
caused more mucosal injury.
In the present study, the mean airway leak pressure was
higher with the LMA-Protector™ (31 cmH2O) than with
the i-gel™ (27 cmH2O), consistent with the results of the
previous studies showing values of 23–29 cmH2O for the i-
gel™ [5, 9, 10, 12]. The oropharyngeal airway seal, quanti-
fied by the airway leak pressure, is essential for the preven-
tion of aspiration and ventilator efficiency. Higher airway
leak pressure results from the closer contact between the
cuff and the adjacent soft tissues. The LMA-Protector™
cuff, made of medical-grade silicone, may provide a more
individualized fit in the pharynx and hypopharynx. Accord-
ing to a preliminary evaluation, the median pharyngeal seal
pressure of the LMA-Protector™ was 34 cmH2O [8]. In
another preliminary assessment in non-paralyzed female
patients with the LMA-Protector™ size three [7], median
oropharyngeal leak pressure was 25.2 cmH2O. In the
present study, we used the different sized devices (size
three, four or five) according to the manufacturer’s recom-
mendation based on the patient’s weight in paralyzed males
and females. Several factors such as the use of neuromus-
cular blockade and the size of the device, may have affected
the airway leak pressure.
In the present study, the mean airway leak pressure
was slightly higher with the LMA-Protector™ than with
Fig. 2 Study flowchart





Age (years) 59 (14) 57 (18)
Gender (M/F) 28/27 27/28
Weight (kg) 65 (9) 64 (11)
Height (cm) 163 (7) 163 (8)
Postoperative analgesia
PCA with fentanyl 32 33






Orthopedic surgery 25 28
Urologic surgery 20 20
General surgery 10 7
Duration of surgery (min) 59 (31) 58 (38)
Duration of anesthesia (min) 90 (32) 91 (41)
Values are means (SD) or number of patients. PCA,
patient-controlled analgesia
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the i-gel™, which might be clinically insignificant. How-
ever, this result should not be ignored because it may
also suggest that the LMA-Protector™ can be a choice in
some clinical situations where a higher airway leak pres-
sure is required such as laparoscopic surgery, although it
was not evaluated in this study.
The success rate of the device insertion at the first at-
tempt (91% vs. 93%, LMA-Protector™ vs. i-gel™, respect-
ively), and ease of insertion were not different between
the two devices, but the insertion time was longer with
the LMA-Protector™ than with the i-gel™. The i-gel™ has
a non-inflatable cuff, whereas the LMA-Protector™ has a
longer and larger inflatable cuff, therefore, it might take
more time to introduce the larger cuff into the oropha-
ryngeal space and inflate it. Moreover, anesthesiologists
had more familiarity with the i-gel™ than the LMA-
Protector™, which may influence insertion time.
The i-gel™ and LMA-Protector™ can be used as an in-
tubation conduit, and proper alignment of the ventila-
tion pathway with the vocal cords is crucial for
successful tracheal intubation. In the present study, ven-
tilation was adequate in all patients, but the i-gel™ had a
better fiberoptic view of the glottis with less epiglottic
down-folding than the LMA-Protector™. This finding
was consistent with previous studies in which the i-gel™
provided an acceptable fiberoptic view of the vocal cords
in more than 80% of subjects [5, 10]. The i-gel™ has an
epiglottic rest preventing the epiglottis from down-
folding or obstructing the distal opening the airway [1],
whereas the LMA-Protector™ has no component to
prevent epiglottic down-folding, such as the epiglottic
elevating bar in the LMA-Fastrach™ [13, 14].
The i-gel™ has one gastric channel, similar to other
pre-existing supraglottic airway devices. The newly de-
veloped LMA-Protector™ distinctively contains two gas-
tric channels, a suction port and a drainage port, which
emerge proximally as separate ports, entered a chamber
located behind the cuff bowl, and communicates distally
with the upper esophageal sphincter (Fig. 1). The gastric






Number of insertion attempts
one 51 (93) 50 (91) 1.000
two 4 (7) 5 (9)
three 0 (0) 0 (0)
Insertion time (sec) 19 (16) 27 (16) < 0.001
Airway leak pressure (cmH2O) 27 (6) 31 (7) 0.016
Ease of insertion
Easy 45 (82) 37 (67) 0.125
Fair 10 (18) 18 (33)
Difficult 0 (0) 0 (0)
Fibreoptic examination
Only vocal cords 44 (80) 9 (16) < 0.001
Vocal cords and posterior part of the epiglottis 8 (15) 28 (51)
Vocal cords and anterior part of the epiglottis 3 (5) 11 (20)
Vocal cords not seen, but adequate ventilation 0 (0) 7 (13)
Ease of gastric tube insertion
First attempt 51 (93) 27 (49) < 0.001
Second attempt 3 (5) 19 (35)
Impossible 1 (2) 9 (16)
Blood staining on the device 4 (7) 13 (24) 0.033
Values are means (SD) or number of patients (%)







1 h after surgery 11 (20) 16 (29) 0.376
24 h after surgery 8 (15) 9 (16) 1.000
Severity
1 h after surgery 4 (11) 9 (17) 0.168
24 h after surgery 3 (7) 3 (8) 0.794
Values are means (SD) or number of patients (%). Severity of postoperative
sore throat was assessed using a 0- to 100-mm numerical rating scale (0, no
pain; 100, worst pain imaginable)
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fluid can be removed by attaching suction to the suction
port or by inserting a gastric tube through the drainage
port to the stomach. The internal volume of the drain-
age pathway in the LMA-Protector™ (31 mL for size
three; 41 mL for size four; 42 mL for size five) [13] is
much larger than that of the i-gel™. Thus, the LMA-
Protector™ may be more efficient at reducing the risk of
pulmonary aspiration of gastric contents. Nevertheless, in
the present study, the gastric tube insertion was more diffi-
cult through the LMA-Protector™ than through the i-gel™
despite of adequate ventilation in all patients. We failed to
insert the gastric tube in nine patients through the LMA-
Protector™ and one patient through the i-gel™. This finding
might be associated with the size of the gastric tube used
with the LMA-Protector™. According to the instructions
for use of each device, the recommended maximum size of
the gastric tube was 12 or 14 Fr for the i-gel™ (12 Fr for
sizes three and four; 14 Fr for size five) and 16 or 18 Fr for
the LMA-Protector™ (16 Fr for size three; 18 Fr for sizes
four and five) [1, 6]. In the present study, we used the gas-
tric tube size 12 Fr for the i-gel™ and size 14 Fr for the
LMA-Protector™. The selection of the 14 Fr gastric tube for
the LMA-Protector™ was based on a preliminary study
using the LMA-Protector™ size three in female patients in
which the 14 Fr gastric tube was successfully inserted in 24
of 25 patients [7]. In this study, we inserted the 14 Fr gastric
tube through the size three, four or five LMA-Protector™,
and considered that it was difficult to introduce the rela-
tively thin and flexible gastric tube within the large drainage
pathway. Thus, the use of a larger sized gastric tube might
facilitate the passage through the gastric channel of the
LMA-Protector™ although it was not evaluated in this
study. Moreover, the LMA-Protector™ has a large gastric
pathway, which may provide a potential advantage at risk
of pulmonary aspiration. Thus, a further study is required
regarding the protective effect of the LMA-Protector™
against pulmonary aspiration.
In the present study, blood staining indicative of muco-
sal injury was more frequent with the LMA-Protector™
(24%) than with the i-gel™ (7%). In some previous studies,
blood staining was observed in 0–13% of patients with the
i-gel™ [9, 15–17]. The i-gel™ has a non-inflatable cuff made
of a soft, gel-like medical-grade thermoplastic elastomer,
potentially reducing the oropharyngeal tissue injury [18].
Although the LMA-Protector™ is made of flexible
medical-grade silicone, it has a strongly tapered leading
tip and a longer and larger inflatable cuff compared to the
i-gel™, which may cause more mucosal injury. The inci-
dence and severity of postoperative sore throat, however,
were not different between the two devices.
This study had several limitations. First, the investiga-
tors who inserted the supraglottic airway device were not
blinded to the group assignment due to the nature of the
study. They followed the standardized and detailed study
protocol. The investigators that evaluated postoperative
sore throat, and all patients were blinded to the group al-
location. Yet, there is still the potential for bias. Second,
the investigators who inserted the supraglottic airway de-
vice had more experience with the i-gel™ (more than 100
insertions) than with the LMA-Protector™ (more than 30
insertions). They did have experience with more than 50
insertions of the LMA-Supreme™ which has a similar
insertion method to the LMA-Protector™. However, a
conscious (or unconscious) bias against the newer device,
LMA-Protector™, might affect the results. Furthermore,
the difference in experience with the two devices, espe-
cially less experience with the newer device, may be a pos-
sible source of bias. Third, this study was performed in
anesthetized and paralyzed patients with normal airways.
Thus, our results cannot be generalized to non-paralyzed
patients, patients during spontaneous ventilation, and
patients with difficult airways. Fourth, this study was
conducted in patients with a mean body mass index of 24
kg/m2, not in obese patients, and our results may not be
applicable to obese patients.
Conclusions
LMA-Protector™ provided a higher airway sealing effect,
but provided a worse fiberoptic view of the vocal cords,
and caused more mucosal injury compared to the i-gel™.
The gastric tube placement was more difficult with the
LMA-Protector™ than with the i-gel™, however this may
be related to the gastric tube size used in our study. A lar-
ger sized gastric tube, within the range of recommended
sizes, might better facilitate the passage through the gas-
tric channel of the LMA-Protector™. Moreover, the LMA-
Protector™ has a distinctively large gastric pathway, and a
further study is required regarding the protective effect of
the LMA-Protector™ against pulmonary aspiration.
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